
|Videos|June 9, 2022
Dr. Roger Li on CG0070 combined with pembrolizumab in NMIBC unresponsive to BCG
Author(s)Urology Times staff
“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.
Advertisement
In this video, Roger Li, MD, discusses the 2022 ASCO Annual Meeting study, “CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).” Li is a genitourinary oncologist at Moffitt Cancer Center in Tampa, Florida.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Choosing salvage therapy after prostate cancer focal ablation
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
4
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
5


















